Altamira Therapeutics Ltd
NASDAQ:CYTO
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| CH |
|
Altamira Therapeutics Ltd
NASDAQ:CYTO
|
319.9k USD |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
973.3B USD |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
572.1B USD |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
284.4B CHF |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
302.3B USD |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
217.3B GBP |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
227.3B CHF |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.3T DKK |
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
153.8B USD |
Loading...
|
|
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
119.5B USD |
Loading...
|
Market Distribution
| Min | -57 027.8% |
| 30th Percentile | 1.3% |
| Median | 7.2% |
| 70th Percentile | 13.7% |
| Max | 3 663.7% |
Other Profitability Ratios
Altamira Therapeutics Ltd
Glance View
Altamira Therapeutics Ltd. engages in the development of novel products that address unmet medical needs in neurology and central nervous system disorders.
See Also
Net Margin is calculated by dividing the Net Income by the Revenue.
The current Net Margin for Altamira Therapeutics Ltd is -11.5%, which is above its 3-year median of -3 870.7%.
Over the last 3 years, Altamira Therapeutics Ltd’s Net Margin has increased from -28 433.3% to -11.5%. During this period, it reached a low of -28 433.3% on Dec 31, 2021 and a high of -11.5% on Jul 30, 2024.
